Symbols

GUTS

Fractyl Health·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

Stock Price Surged Significantly

Gap Up

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About GUTS

Fractyl Health, Inc.

A diabetes and obesity therapy research and development company

Industry

Life Science Tools and Services

Established Date

08/30/2010

Listing Date

02/02/2024

Exchange

NASDAQ Stock Exchange

Full-time Employees

100

Fiscal Year Ends

12-31

Website

ir.fractyl.com

Security Type

Common stock

Office address

3 Van de Graaff Drive, Suite 200, Burlington, MA 01803

Business

Introduction

Fractyl Health, Inc., was incorporated in Delaware on August 30, 2010. The company is a clinical-stage metabolic therapy company focused on developing new approaches to treat obesity and type 2 diabetes. Its lead product candidate, the Revita DMR System, is designed to reshape the duodenal mucosa to address the underlying cause of metabolic disease.

Company Financials

EPS

GUTS has released its 2025 Q4 earnings. EPS was reported at -0.31, versus the expected -0.41, beating expectations. The chart below visualizes how GUTS has performed over recent quarters, highlighting trends in earnings surprises.